vs

Side-by-side financial comparison of Fortress Biotech, Inc. (FBIO) and Ispire Technology Inc. (ISPR). Click either name above to swap in a different company.

Ispire Technology Inc. is the larger business by last-quarter revenue ($20.3M vs $16.1M, roughly 1.3× Fortress Biotech, Inc.). Fortress Biotech, Inc. runs the higher net margin — -24.5% vs -32.5%, a 8.0% gap on every dollar of revenue. On growth, Fortress Biotech, Inc. posted the faster year-over-year revenue change (6.3% vs -51.5%). Over the past eight quarters, Fortress Biotech, Inc.'s revenue compounded faster (11.0% CAGR vs -17.8%).

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.

FBIO vs ISPR — Head-to-Head

Bigger by revenue
ISPR
ISPR
1.3× larger
ISPR
$20.3M
$16.1M
FBIO
Growing faster (revenue YoY)
FBIO
FBIO
+57.8% gap
FBIO
6.3%
-51.5%
ISPR
Higher net margin
FBIO
FBIO
8.0% more per $
FBIO
-24.5%
-32.5%
ISPR
Faster 2-yr revenue CAGR
FBIO
FBIO
Annualised
FBIO
11.0%
-17.8%
ISPR

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
FBIO
FBIO
ISPR
ISPR
Revenue
$16.1M
$20.3M
Net Profit
$-3.9M
$-6.6M
Gross Margin
66.1%
17.1%
Operating Margin
-28.8%
-33.9%
Net Margin
-24.5%
-32.5%
Revenue YoY
6.3%
-51.5%
Net Profit YoY
41.8%
17.4%
EPS (diluted)
$-0.15
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FBIO
FBIO
ISPR
ISPR
Q4 25
$16.1M
$20.3M
Q3 25
$17.6M
$30.4M
Q2 25
$16.4M
$20.1M
Q1 25
$13.1M
$26.2M
Q4 24
$15.1M
$41.8M
Q3 24
$14.6M
$39.3M
Q2 24
$14.9M
$37.3M
Q1 24
$13.0M
$30.0M
Net Profit
FBIO
FBIO
ISPR
ISPR
Q4 25
$-3.9M
$-6.6M
Q3 25
$5.8M
$-3.3M
Q2 25
$15.5M
$-14.8M
Q1 25
$-10.6M
$-10.9M
Q4 24
$-6.8M
$-8.0M
Q3 24
$-12.9M
$-5.6M
Q2 24
$-10.9M
$-3.5M
Q1 24
$-15.4M
$-5.9M
Gross Margin
FBIO
FBIO
ISPR
ISPR
Q4 25
66.1%
17.1%
Q3 25
67.4%
17.0%
Q2 25
69.9%
12.3%
Q1 25
63.5%
18.2%
Q4 24
69.1%
18.5%
Q3 24
69.4%
19.5%
Q2 24
61.6%
28.3%
Q1 24
53.9%
20.4%
Operating Margin
FBIO
FBIO
ISPR
ISPR
Q4 25
-28.8%
-33.9%
Q3 25
-38.6%
-8.9%
Q2 25
-222.2%
-72.7%
Q1 25
-169.9%
-40.4%
Q4 24
-158.3%
-17.6%
Q3 24
-151.0%
-13.4%
Q2 24
-186.5%
-9.2%
Q1 24
-280.6%
-18.8%
Net Margin
FBIO
FBIO
ISPR
ISPR
Q4 25
-24.5%
-32.5%
Q3 25
33.2%
-10.7%
Q2 25
94.4%
-73.4%
Q1 25
-80.6%
-41.5%
Q4 24
-44.7%
-19.1%
Q3 24
-88.0%
-14.2%
Q2 24
-73.5%
-9.4%
Q1 24
-118.3%
-19.7%
EPS (diluted)
FBIO
FBIO
ISPR
ISPR
Q4 25
$-0.15
$-0.12
Q3 25
$0.11
$-0.06
Q2 25
$0.45
$-0.26
Q1 25
$-0.48
$-0.19
Q4 24
$-0.16
$-0.14
Q3 24
$-0.76
$-0.10
Q2 24
$-0.73
$-0.07
Q1 24
$-1.04
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FBIO
FBIO
ISPR
ISPR
Cash + ST InvestmentsLiquidity on hand
$79.4M
$17.6M
Total DebtLower is stronger
$52.4M
Stockholders' EquityBook value
$49.9M
$-7.7M
Total Assets
$185.5M
$84.4M
Debt / EquityLower = less leverage
1.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FBIO
FBIO
ISPR
ISPR
Q4 25
$79.4M
$17.6M
Q3 25
$86.2M
$22.7M
Q2 25
$74.4M
$24.4M
Q1 25
$91.3M
$23.5M
Q4 24
$57.3M
$34.4M
Q3 24
$58.9M
$37.7M
Q2 24
$76.2M
$35.1M
Q1 24
$83.8M
$39.5M
Total Debt
FBIO
FBIO
ISPR
ISPR
Q4 25
$52.4M
Q3 25
$47.8M
Q2 25
$50.0M
Q1 25
$56.4M
Q4 24
$58.0M
Q3 24
$52.5M
Q2 24
$67.0M
Q1 24
$61.4M
Stockholders' Equity
FBIO
FBIO
ISPR
ISPR
Q4 25
$49.9M
$-7.7M
Q3 25
$55.9M
$-1.8M
Q2 25
$43.9M
$604.7K
Q1 25
$22.3M
$14.8M
Q4 24
$22.7M
$24.2M
Q3 24
$21.2M
$30.7M
Q2 24
$17.9M
$34.5M
Q1 24
$23.0M
$35.9M
Total Assets
FBIO
FBIO
ISPR
ISPR
Q4 25
$185.5M
$84.4M
Q3 25
$181.4M
$96.4M
Q2 25
$159.9M
$102.2M
Q1 25
$178.1M
$115.7M
Q4 24
$144.2M
$132.0M
Q3 24
$127.1M
$129.0M
Q2 24
$145.7M
$122.6M
Q1 24
$164.6M
$108.0M
Debt / Equity
FBIO
FBIO
ISPR
ISPR
Q4 25
1.05×
Q3 25
0.86×
Q2 25
1.14×
Q1 25
2.53×
Q4 24
2.55×
Q3 24
2.48×
Q2 24
3.75×
Q1 24
2.67×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FBIO
FBIO
ISPR
ISPR
Operating Cash FlowLast quarter
$-12.5M
$-4.0M
Free Cash FlowOCF − Capex
$-4.0M
FCF MarginFCF / Revenue
-19.9%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-14.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FBIO
FBIO
ISPR
ISPR
Q4 25
$-12.5M
$-4.0M
Q3 25
$-6.1M
$-1.2M
Q2 25
$-27.6M
$4.7M
Q1 25
$-19.6M
$-12.5M
Q4 24
$-12.9M
$-3.2M
Q3 24
$-20.1M
$3.6M
Q2 24
$-21.8M
$-1.4M
Q1 24
$-25.4M
$3.4M
Free Cash Flow
FBIO
FBIO
ISPR
ISPR
Q4 25
$-4.0M
Q3 25
$-1.2M
Q2 25
$3.7M
Q1 25
$-12.7M
Q4 24
$-3.2M
Q3 24
$3.3M
Q2 24
$-2.2M
Q1 24
$3.3M
FCF Margin
FBIO
FBIO
ISPR
ISPR
Q4 25
-19.9%
Q3 25
-3.9%
Q2 25
18.6%
Q1 25
-48.4%
Q4 24
-7.7%
Q3 24
8.5%
Q2 24
-5.9%
Q1 24
10.9%
Capex Intensity
FBIO
FBIO
ISPR
ISPR
Q4 25
0.3%
Q3 25
0.0%
Q2 25
4.8%
Q1 25
0.7%
Q4 24
0.1%
Q3 24
0.0%
0.7%
Q2 24
2.0%
Q1 24
0.3%
Cash Conversion
FBIO
FBIO
ISPR
ISPR
Q4 25
Q3 25
-1.04×
Q2 25
-1.78×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons